# Study to Assess PK, Safety and Tolerability in Healthy Subjects

> **NCT06380699** · PHASE1 · COMPLETED · sponsor: **Changzhou Qianhong Bio-pharma Co., Ltd.** · enrollment: 56 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** QHRD106 Injection
- **DRUG:** Human Urinary Kallidinogenase
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06380699
- **Lead sponsor:** Changzhou Qianhong Bio-pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-16
- **Primary completion:** 2023-11-16
- **Final completion:** 2023-12-25
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06380699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06380699, "Study to Assess PK, Safety and Tolerability in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06380699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*